Literature DB >> 12528305

Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis.

Patrick Weydt1, Michael D Weiss, Thomas Möller, Gregory T Carter.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neuromuscular disease that destroys both upper and lower motor neurons, resulting in spasticity, diffuse muscular atrophy, weakness, and ultimately death from respiratory failure. It is presumed that in the vast majority of cases, ALS is acquired and occurs sporadically, although the exact etiology is unknown. Recent, emerging evidence suggests that neuro-inflammation may be a pathological characteristic of this disease; this could represent a potential therapeutic target for a pharmacological agent to help treat this severe disease. This article reviews the current research in this area and discusses theoretical and clinical ramifications of these recent findings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12528305

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  9 in total

1.  Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms.

Authors:  Weihua Zhao; David R Beers; Bing Liao; Jenny S Henkel; Stanley H Appel
Journal:  Neurobiol Dis       Date:  2012-07-17       Impact factor: 5.996

2.  The Nogo/Nogo Receptor (NgR) Signal Is Involved in Neuroinflammation through the Regulation of Microglial Inflammatory Activation.

Authors:  Yinquan Fang; Jun Yan; Chenhui Li; Xiao Zhou; Lemeng Yao; Tao Pang; Ming Yan; Luyong Zhang; Lei Mao; Hong Liao
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

3.  The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.

Authors:  Burkhard Schütz; Jens Reimann; Lucia Dumitrescu-Ozimek; Karin Kappes-Horn; Gary E Landreth; Britta Schürmann; Andreas Zimmer; Michael T Heneka
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

Review 4.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cells.

Authors:  Michael S Thomas; Wenru Zhang; Paivi M Jordan; H Uri Saragovi; Giulio Taglialatela
Journal:  J Neuroinflammation       Date:  2005-09-06       Impact factor: 8.322

Review 6.  Plant-Derived Natural Compounds for the Treatment of Amyotrophic Lateral Sclerosis: An Update.

Authors:  Roohi Mohi-Ud-Din; Reyaz Hassan Mir; Abdul Jalil Shah; Saba Sabreen; Taha Umair Wani; Mubashir Hussain Masoodi; Esra Küpeli Akkol; Zulfiqar Ali Bhat; Haroon Khan
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

7.  Melittin ameliorates the inflammation of organs in an amyotrophic lateral sclerosis animal model.

Authors:  Sun-Hwa Lee; Sun-Mi Choi; Eun Jin Yang
Journal:  Exp Neurobiol       Date:  2014-03-27       Impact factor: 3.261

8.  Thymic involution, a co-morbidity factor in amyotrophic lateral sclerosis.

Authors:  Akop Seksenyan; Noga Ron-Harel; David Azoulay; Liora Cahalon; Michal Cardon; Patricia Rogeri; Minhee K Ko; Miguel Weil; Shlomo Bulvik; Gideon Rechavi; Ninette Amariglio; Eli Konen; Maya Koronyo-Hamaoui; Raz Somech; Michal Schwartz
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

9.  Early gene expression changes in spinal cord from SOD1(G93A) Amyotrophic Lateral Sclerosis animal model.

Authors:  Gabriela P de Oliveira; Chrystian J Alves; Gerson Chadi
Journal:  Front Cell Neurosci       Date:  2013-11-18       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.